Finishing sooner than you want is one of the most common sexual worries men have, and the internet often offers a simple answer: take an erection pill. The labels for Viagra and Cialis, the US urology guideline and the research tell a more careful story, and it depends a lot on whether erections are part of the problem.
- Approved use: Viagra (sildenafil) is labeled for erectile dysfunction (ED); Cialis (tadalafil) for ED and for urinary symptoms of an enlarged prostate. Neither label lists premature ejaculation (PE).
- Guideline position: the 2020 AUA/SMSNA ejaculation guideline names SSRIs, on-demand clomipramine or dapoxetine, and numbing creams or sprays as first-line PE medicines. PDE5 inhibitors are not on that list.
- When ED is also present: the same guideline says to treat it according to the AUA erectile dysfunction guideline.
- Research: meta-analyses found longer time to ejaculation with PDE5 inhibitors than with placebo, but in trials of mixed or unclear quality.
Maybe it happened once and has been on your mind since. Maybe it has been true for as long as you can remember. Either way, it is worth separating two questions that often get blended together: does an ED medicine help you keep an erection, and does it change when you ejaculate? The first has a clear answer on the label. The second does not.
What the Viagra and Cialis labels actually cover
The Viagra prescribing information on DailyMed has a one-line indication: Viagra “is indicated for the treatment of erectile dysfunction.” The Cialis prescribing information lists three uses: erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia (BPH), and both together. Premature ejaculation does not appear in either indication section. The only ejaculation-related wording we found in the two labels is “abnormal ejaculation” in a Viagra adverse-event list.
Both labels also explain how the drugs work, which matters for this question. The Cialis label states that because sexual stimulation is needed to start the local release of nitric oxide, inhibition of PDE5 by tadalafil “has no effect in the absence of sexual stimulation.” The Viagra label makes the same point for sildenafil. These medicines support blood flow into the penis. The labels do not describe any action on the reflex that triggers ejaculation.
The patient information for Cialis adds that it does not cure ED and does not increase a man’s sexual desire. So if a prescriber uses either drug for PE, that use is off label, a clinical decision made outside what the FDA reviewed for approval.
What the US urology guideline says
The Disorders of Ejaculation guideline from the American Urological Association and the Sexual Medicine Society of North America (2020) is the main US reference. Several of its statements bear directly on the question.
First, how PE is defined. Lifelong PE is described as poor ejaculatory control, associated bother, and ejaculation within about 2 minutes of starting penetrative sex, present since sexual debut. Acquired PE means consistently poor control and bother, with latency markedly shorter than the man’s own past experience. The bother part is central: a stopwatch number on its own is not a diagnosis.
Second, the medicines. The guideline’s first-line statement reads: “Clinicians should recommend daily SSRIs; on demand clomipramine or dapoxetine (where available); and topical penile anaesthetics as first-line pharmacotherapies in the treatment of premature ejaculation.” It is graded a Strong Recommendation. Tramadol and alpha-blockers are listed as options after first-line treatment fails. PDE5 inhibitors appear in the guideline’s overview of drugs that “have been utilized” for PE, but not among its recommended treatments for men with PE alone.
Third, the overlap with erections. A separate statement says clinicians should treat comorbid erectile dysfunction in men with PE according to the AUA guideline on ED (Expert Opinion). The discussion adds that men with acquired PE should get treatment aimed at the cause when one can be found, with “appropriate pharmacotherapy for men with ED” given as an example.
MedlinePlus, from the National Library of Medicine, takes a similarly cautious line in its premature ejaculation page: it describes stop-start and squeeze techniques, SSRIs and numbing creams, and says that “other medicines used for erectile dysfunction may help,” adding that combining behavioral techniques with medicine may work best.
If erections are fine and the only issue is timing, ED pills are not what the US guideline recommends first. If you also lose erections, or rush because you fear losing them, treating the ED is part of the plan, and an ED medicine may then be the right tool for that part.
What the studies measured, and what they found
Researchers have tested PDE5 inhibitors for PE for more than two decades. The main outcome is usually intravaginal ejaculatory latency time (IELT), the time from penetration to ejaculation, often measured with a partner-held stopwatch. Some trials also asked about perceived control and satisfaction.
| Study | What it looked at | Main finding | Caveat the authors gave |
|---|---|---|---|
| McMahon et al., J Sex Med 2005 | 8-week placebo-controlled trial of sildenafil in men aged 18–65 with diagnosed PE | Change in IELT was larger with sildenafil but not statistically significant; ejaculatory control, confidence and satisfaction scores improved; refractory time to a second erection fell | Headache and flushing each in 15% of sildenafil users vs. 1% and 0% on placebo |
| Asimakopoulos et al., J Sex Med 2012 | Systematic review and meta-analysis of PDE5 inhibitors in PE without ED | Overall positive effect as monotherapy or in combination | Concluded there is “inadequate, partial basic, and clinical evidence” to support PDE5 use for PE; poor study design and no single PE definition |
| Martyn-St James et al., Eur Urol Focus 2017 | 15 randomized trials | PDE5 inhibitors beat placebo on IELT; no difference vs. SSRIs; PDE5 plus SSRI beat SSRI alone | Most trials of unclear methodological quality; high heterogeneity; single trials found lidocaine gel and tramadol more effective than sildenafil |
| Zhang et al., Am J Mens Health 2020 | 7 placebo-controlled trials, 471 patients | Mean IELT gain of 2.60 minutes over placebo; better satisfaction scores | More side effects with PDE5 inhibitors, such as headache, dizziness, flushing and nasal congestion |
Read together, the research suggests some men in some trials lasted longer on a PDE5 inhibitor than on placebo. The reviewers themselves flagged why that is not the same as a proven PE treatment: small trials, different definitions of PE, and in many cases unclear blinding or randomization. That gap between “a signal in studies” and “recommended treatment” is exactly where the AUA/SMSNA guideline sits.
Why ED and PE get mixed up
For many men the two problems feed each other. Someone who is worried about losing an erection may hurry, which shortens time to ejaculation. Someone who ejaculates quickly may start to feel anxious about sex in general, and anxiety can affect erections. The AUA/SMSNA guideline notes the association between PE, comorbid ED, metabolic syndrome, a sedentary lifestyle, alcohol use and body mass index, and asks clinicians to counsel on exercise and healthy habits.
This is also why personal stories online are so mixed. A man whose real problem was a fading erection may say an ED pill “made him last longer,” because sex no longer ended early when the erection faded. A man with lifelong PE and normal erections may notice little change in timing. Both accounts can be honest and still point in different directions.
If you are not sure which pattern fits you, a clinician will usually ask about timing, control, how long the problem has existed, whether it happens with every partner and during masturbation, and whether erections are firm enough. The guideline recommends a medical, relationship and sexual history plus a focused physical exam, and advises against routine extra testing for lifelong PE. Our overview of how erectile dysfunction is diagnosed and treated explains the ED side of that conversation.
The “second round” claim
A common claim is that Viagra lets you go again sooner. There is a published basis for part of it. In the 2005 McMahon trial, men with PE who took sildenafil had a shorter postejaculatory refractory time to a second erection than men on placebo (3.2 vs. 6.4 minutes, from a crossover substudy in a subset of patients). The 2012 review lists a shorter refractory time among possible effects as well.
Two cautions. Those figures come from a small substudy, not from a large set of trials. And a quicker second erection does not change how soon ejaculation happens the first time. The AUA/SMSNA guideline also notes that the refractory period tends to get longer with age, which is normal physiology rather than a disorder.
Safety does not change because the goal is different
Whatever the reason a PDE5 inhibitor is prescribed, the label warnings come with it. Both are contraindicated with any form of organic nitrate and with riociguat, and both carry warnings about sudden vision or hearing loss and erections lasting more than 4 hours. Our guides to PDE5 warning signs for vision, hearing and priapism and how long Viagra lasts cover those details. Using someone else’s tablets, or combining a PDE5 inhibitor with an SSRI on your own, skips the medication and heart review a prescriber would do.
FAQ
Will Viagra or Cialis make me last longer if my erections are normal?
Neither drug is approved for that. Some trials and meta-analyses report longer time to ejaculation than placebo, but reviewers rated much of that evidence as limited, and the AUA/SMSNA guideline does not list PDE5 inhibitors among first-line PE treatments.
What does the US guideline recommend first for premature ejaculation?
Daily SSRIs, on-demand clomipramine or dapoxetine where available, and topical penile anesthetics, along with the advice that combining behavioral and medical approaches may work better than either alone. Dapoxetine is named with the caveat “where available.” Referral to a mental health professional with sexual health expertise is also part of the guideline.
I have both problems. Will an ED pill help?
The guideline says ED in a man with PE should be treated according to the ED guideline. Whether a PDE5 inhibitor is part of that, alone or with a PE treatment, is a prescriber decision that depends on your heart health, other medicines and what is driving each problem.
Does Cialis work differently from Viagra for this?
Both are PDE5 inhibitors with the same mechanism. The Cialis label describes improved erectile function compared with placebo up to 36 hours after a dose and adds BPH indications; neither label addresses ejaculation timing. The reviews in the table pooled several PDE5 inhibitors, so they do not give a clear answer about which one, if any, helps timing more.
When should I talk to someone?
MedlinePlus suggests contacting a provider if PE is a problem for you, especially if it does not improve with self-help techniques. MedlinePlus’s overview of sexual problems in men also advises seeing a provider if problems last more than a few months or cause distress for you or a partner, which includes new trouble with erections.
Sources
- DailyMed: Viagra (sildenafil) prescribing information
- DailyMed: Cialis (tadalafil) prescribing information
- AUA/SMSNA: Disorders of Ejaculation guideline (2020)
- MedlinePlus: Premature ejaculation
- MedlinePlus: Sexual problems in men
- McMahon CG et al. J Sex Med 2005: sildenafil in men with PE
- Asimakopoulos AD et al. J Sex Med 2012: PDE5 inhibitors for PE, systematic review
- Martyn-St James M et al. Eur Urol Focus 2017: PDE5 inhibitors for PE, meta-analysis
- Zhang X et al. Am J Mens Health 2020: placebo-controlled meta-analysis
Evidence checked November 2, 2026. This article explains published labels, guidance and studies; it is not a treatment recommendation. Decisions about any medicine belong with your prescriber.